herp
simplex
viru
infect
cell
massiv
present
viral
replic
aim
investig
possibl
target
core
extend
naphtalen
diimid
cexndi
ligand
biophys
biomolecular
analysi
prove
cexndi
stabil
concentr
depend
manner
ms
competit
assay
cexndi
preferenti
recogn
cellular
telomer
repres
within
cell
less
abund
cellular
also
recogn
treatment
infect
cell
cexndi
low
nanomolar
concentr
induc
signific
viru
inhibit
cytotox
mechan
action
ascrib
inhibit
viral
dna
replic
consequ
impair
viral
gene
transcript
data
suggest
observ
potent
antivir
activ
low
cytotox
mainli
depend
combin
cexndi
affin
massiv
presenc
infect
may
thu
repres
new
effect
antivir
target
fact
current
antiherpet
drug
exploit
presenc
viral
genom
respons
activ
latent
hsv
infect
make
particularli
attract
gquadruplex
nucleic
acid
secondari
structur
may
form
singlestrand
grich
sequenc
physiolog
condit
four
gs
bind
via
hoogsteentyp
hydrogen
bond
basepair
yield
gquartet
stack
form
presenc
k
cation
specif
support
format
stabil
base
strand
orient
adopt
three
main
topolog
parallel
antiparallel
hybridtyp
structur
eukaryot
shown
involv
key
regulatori
role
includ
transcript
regul
gene
promot
enhanc
translat
chromatin
epigenet
regul
dna
recombin
expans
gquadruplexform
motif
associ
relev
human
neurolog
disord
format
vivo
consolid
discoveri
cellular
protein
specif
recogn
develop
specif
antibodi
recent
presenc
virus
involv
viru
key
step
provid
implic
pathogen
mechan
human
immunodefici
viru
function
signific
identifi
stabil
ligand
consequ
antivir
effect
report
sar
coronaviru
human
papilloma
zika
ebola
hepat
c
viru
genom
among
herpesvirus
rna
implic
regul
dna
replic
translat
epsteinbarr
viru
shown
herp
simplex
viru
possess
sever
repeat
import
sequenc
could
stabil
ligand
inhibit
viral
dna
replic
addit
visual
aid
antibodi
infect
cell
shown
form
massiv
cell
nucleu
peak
viral
replic
local
accord
viral
genom
intracellular
movement
involv
structur
sever
human
diseas
propel
develop
small
molecul
direct
howev
test
virus
ie
publish
xx
xx
xxxx
open
wwwnaturecomscientificreport
scientif
report
pyridostatin
ebv
coreextend
naphtalen
diimid
compound
cexndi
sinc
definit
drug
found
viral
infect
obviou
need
new
activ
compound
cexndi
deriv
shown
display
fair
select
toward
form
ltr
viral
promot
versu
cellular
select
rest
prefer
recognit
loop
region
vs
cellular
sought
investig
best
compound
seri
cexndi
previou
work
display
also
activ
test
mechan
action
found
cexndi
abl
bind
stabil
form
sequenc
concentr
depend
manner
treatment
infect
cell
cexndi
induc
complet
inhibit
viru
low
nanomolar
concentr
mechan
action
direct
toward
viral
dna
replic
inhibit
viral
dna
replic
impair
viral
gene
transcript
result
effect
antiherpet
effect
ms
competit
assay
demonstr
cexndi
preferenti
bind
cellular
telomer
repres
within
cell
suggest
observ
preferenti
antivir
activ
vs
cytotox
mediat
higher
amount
cell
higher
affin
cexndi
ligand
cexndi
highli
stabil
previous
shown
cexndi
compound
specif
develop
inde
abl
select
recogn
bind
high
affin
sequenc
human
telomer
sequenc
form
promot
oncogen
also
bound
albeit
lower
affin
test
possibl
expand
antivir
activ
evalu
abil
lead
member
cexndi
famili
cexndi
herein
call
cexndi
interact
also
form
termin
repeat
three
sequenc
consid
two
sequenc
form
fourstackedgquartet
structur
one
form
threegquartet
stabil
conform
chang
upon
addit
cexndi
detect
circular
dichroism
cd
mm
k
cexndi
stabil
respect
tabl
induc
slight
chang
oligonucleotid
conform
fig
b
case
thermal
unfold
presenc
compound
show
increas
stabil
altern
parallellik
conform
fig
display
start
mm
k
therefor
appreci
valu
could
obtain
howev
mild
cd
spectrum
variat
upon
addit
cexndi
indic
interact
fig
addit
absenc
k
appreci
obtain
cexndi
tabl
data
indic
cexndi
abl
effect
bind
stabil
confirm
increas
stabil
viral
presenc
compound
taq
polymeras
stop
assay
set
templat
correspond
sequenc
tabl
anneal
primer
incub
taq
polymeras
min
sequenc
unabl
fold
alongsid
assay
neg
control
absenc
k
display
mark
stop
site
correspond
first
g
gtract
fig
lane
indic
stabl
fold
stop
site
increas
upon
addit
k
cexndi
fig
lane
moreov
presenc
compound
fulllength
amplifi
product
sharpli
decreas
indic
effect
stabil
thu
inhibit
polymeras
progress
fig
lane
absenc
k
stop
site
observ
sequenc
thu
form
condit
fig
lane
upon
addit
k
cexndi
mark
stop
becam
visibl
gtract
fig
lane
indic
effect
stabil
also
templat
quantif
stop
site
indic
similar
degre
polymeras
stall
induc
compound
three
sequenc
fig
check
select
cexndi
mass
spectrometri
ms
competit
perform
select
competitor
htel
cmyc
correspond
sequenc
human
telomer
repeat
promot
cmyc
oncogen
ckit
protooncogen
ltriii
previous
shown
select
bound
high
affin
cexndi
case
ltriii
prefer
data
confirm
cexndi
select
tabl
cmyc
also
alway
prefer
prefer
vs
contrast
prefer
htel
gener
less
preferenti
bound
analys
sequenc
measur
select
depend
start
stabil
compet
fact
mm
k
prefer
ltriii
cmyc
valu
lower
higher
respect
tabl
contrast
nonpref
similar
valu
tabl
cexndi
display
potent
activ
sinc
data
indic
even
total
prefer
nonetheless
prefer
telomer
abund
cellular
structur
infect
cell
test
abil
cexndi
inhibit
plaqu
assay
compound
show
inhibit
product
ic
nm
fig
interestingli
compound
concentr
abl
kill
cell
measur
mtt
assay
nm
result
remark
select
index
si
fig
confirm
data
recombin
express
gfp
fuse
viral
protein
use
infect
cell
mutant
viru
character
normal
replic
kinet
yield
analysi
perform
flow
cytometri
cell
treat
cexndi
acyclovir
acv
antivir
drug
choic
treatment
infect
use
refer
drug
compar
potenc
cexndi
compound
use
lownon
cytotox
concentr
ie
nm
cexndi
acv
correspond
time
ic
valu
cell
infect
treat
cexndi
acv
hpi
monitor
gfp
fluoresc
cexndi
fig
c
induc
almost
complet
reduct
gfp
fluoresc
express
mean
gfp
fluoresc
wherea
cell
remain
fluoresc
upon
treatment
acv
fig
c
investig
mechan
action
cexndi
mrna
level
repres
viral
gene
measur
hpi
upon
treatment
cexndi
particular
gene
correspond
immediateearli
ie
earli
e
late
l
protein
consid
hpi
signific
inhibit
viral
mrna
product
observ
wherea
hpi
mrna
reduc
similar
extent
fig
similar
trend
report
acv
assess
main
tempor
last
viral
step
target
cexndi
perform
time
addit
toa
assay
maxim
lowmildcytotox
concentr
compound
ad
differ
time
postinfect
correspond
differ
viral
cycl
step
compound
maintain
inhibitori
activ
ad
hpi
fig
time
viral
replic
occur
inde
acv
known
inhibitor
viral
dna
polymeras
show
remark
overlap
toa
profil
data
indic
cexndi
inhibit
viral
product
mainli
target
viral
replic
inhibit
viral
dna
replic
confirm
qpcr
analysi
hpi
reduct
viral
dna
replic
product
observ
wherea
hpi
viral
dna
reduc
fig
similarli
observ
anoth
target
dna
shown
cexndi
compound
initi
develop
specif
interact
potent
stabil
also
found
genom
interestingli
even
net
preferenti
cellular
observ
nevertheless
cexndi
display
potent
activ
parallel
mildlow
toxic
dose
necessari
achiev
complet
suppress
viru
product
fig
ascrib
behaviour
two
main
reason
massiv
presenc
viral
cycl
antibodybas
approach
cell
demonstr
viral
form
massiv
nucleu
viral
tabl
rel
bind
affin
analyz
ms
competit
assay
kit
cmyc
myc
ltriii
oligonucleotid
replic
step
like
control
viral
replic
key
process
infect
consequ
dramat
effect
stabil
cexndi
fact
viral
replic
shown
step
target
cexndi
strongli
point
compound
mechan
action
ii
higher
affin
cexndi
vs
telomer
abund
cellular
infect
cell
lack
optim
recognit
compound
like
main
reason
observ
low
cellular
toxic
antivir
effect
dose
fig
impair
viral
replic
led
decreas
viral
gene
phase
viral
life
cycl
effect
share
cexndi
acv
previous
shown
gener
ligand
mainli
decreas
l
viral
gene
discrep
may
due
lower
affin
lower
antivir
activ
ic
low
micromolar
rang
would
result
observ
inhibit
gene
tempor
close
influenc
inhibit
viral
replic
contrast
case
cexndi
acv
potent
effect
genom
like
sens
extend
level
also
fascin
possibl
cexndi
react
addit
key
regulatori
ie
e
gene
fact
besid
extend
repeat
termin
invert
repeat
less
extend
stabl
structur
also
distribut
throughout
genom
embed
promot
code
sequenc
fundament
gene
uniqu
mechan
action
cexndi
make
suitabl
treatment
strain
resist
current
therapi
instanc
emerg
acv
resist
strain
long
creat
obstacl
treatment
even
though
cexndi
less
wide
therapeut
window
acv
activ
nanomolar
concentr
promis
featur
prospect
develop
antiherpet
drug
sinc
infect
common
ill
associ
immunosuppress
impact
data
extend
aid
cancer
transplant
patient
circular
dichroism
circular
dichroism
cd
experi
perform
use
chirascanplu
appli
photophys
leatherhead
uk
equip
peltier
temperatur
control
use
quartz
cell
mm
path
length
fold
oligonucleotid
dilut
final
concentr
absenc
presenc
mm
kcl
mm
lithium
cacodil
buffer
anneal
step
min
dna
sampl
gradual
cool
specifi
cexndi
ad
final
concentr
thermal
unfold
analys
record
nm
temperatur
rang
report
spectrum
sampl
repres
averag
scan
baselinecorrect
buffer
contribut
observ
ellipt
convert
mean
residu
ellipt
deg
cm
dmol
mol
ellip
valu
calcul
accord
va
nt
hoff
equat
appli
twostat
transit
assum
heat
capac
fold
unfold
state
equal
taq
polymeras
stop
assay
taq
polymeras
stop
assay
perform
previous
describ
briefli
label
primer
hsv
taq
primer
tabl
anneal
templat
tabl
lithium
cacodyl
buffer
specifi
sampl
incub
kcl
mm
presenc
absenc
cexndi
nm
rt
elong
carri
min
use
u
amplitaq
gold
dna
polymeras
appli
biosystem
carlsbad
california
usa
reaction
stop
ethanol
precipit
primer
elong
product
resolv
polyacrylamid
denatur
gel
gel
visual
perform
phosphoimag
typhoon
fla
ge
healthcar
milan
itali
oligonucleotid
heatdenatur
fold
mm
kcl
mm
trimethylammonium
acet
tmaa
ph
isopropanol
ipa
overnight
oligonucleotid
dilut
final
concentr
incub
cexndi
dna
compound
overnight
sampl
analyz
direct
infus
electrospray
ioniz
esi
xevo
qtof
mass
spectromet
water
manchest
uk
inject
automat
perform
agil
infin
hplc
agil
technolog
santa
clara
ca
us
equip
auto
sampler
carri
buffer
tmaa
mm
ipa
sampl
typic
inject
per
analysi
esi
sourc
set
follow
electrospray
capillari
voltag
set
kv
sourc
desolv
temperatur
respect
sampl
cone
set
v
paramet
ensur
minim
fragment
dna
complex
instrument
calibr
use
mgml
solut
sodium
iodid
ipa
bind
affin
calcul
experi
use
reconstructedion
chromatogram
area
speci
calcul
masslynx
bind
affin
calcul
follow
formula
ba
bind
affin
chromatogram
area
bound
dna
chromatogram
area
free
dna
cytotox
assay
cytotox
cexndi
vero
cell
determin
mtt
assay
briefli
serial
dilut
cexndi
dispens
h
plate
vero
cell
cellswel
h
treatment
cell
supplement
freshli
dilut
bromid
mtt
sigmaaldrich
milan
itlay
solut
mgml
incub
h
solubil
absorb
measur
sunris
tecan
plate
reader
mannendorf
switzerland
nm
cytotox
concentr
cc
determin
doserespons
curv
antivir
assay
antivir
activ
cexndi
f
investig
plaqu
assay
viru
infect
wildtyp
wt
f
ad
vero
cell
differ
multipl
infect
moi
serumfre
medium
h
inoculum
replac
complet
medium
infect
compound
ad
increas
concentr
nm
well
singl
round
replic
take
around
h
complet
time
pi
product
viru
reach
plateau
supernat
collect
hpi
store
viral
titrat
plaqu
assay
plaqu
reduct
assay
vero
cell
seed
plate
well
incub
overnight
cell
infect
seriallydilut
supernat
h
infect
cell
wash
pb
incub
dmem
supplement
methylcellulos
fb
fortyeight
hpi
cell
wash
pb
fix
formaldehyd
pb
min
room
temperatur
color
crystal
violet
ethanol
viral
plaqu
count
use
optic
microscop
zeiss
jena
germani
time
addit
assay
time
addit
assay
toa
perform
establish
last
step
viral
infect
cycl
affect
compound
vero
cell
seed
plate
cellswel
incub
overnight
cell
infect
f
moi
suggest
treat
everi
two
hour
hpi
cexndi
nm
acv
refer
drug
allow
estim
cexndi
effect
viral
step
supernat
collect
hpi
titrat
follow
plaqu
assay
work
protocol
describ
flow
cytometri
vero
cell
seed
plate
cellswel
next
day
infect
mutant
express
use
procedur
describ
moi
use
higher
moi
gfp
signal
reach
satur
level
infect
vero
cell
incub
h
complet
medium
complet
medium
contain
cexndi
nm
acv
gfp
fluoresc
acquir
event
sampl
use
fac
cytofluoromet
bd
lsr
ii
bd
bioscenc
new
jersey
usa
fluoresc
acquisit
analyz
flowjo
softwar
tree
star
oregon
usa
trizol
reagent
life
technolog
monza
itali
accord
manufactur
instruct
subject
rnase
free
dnase
treatment
ambion
turbo
dna
free
life
technolog
monza
itali
extract
rna
subject
revers
transcript
u
mulv
life
technolog
monza
itali
revers
transcript
carri
follow
min
min
min
use
thermo
cycler
veriti
appli
biosystem
monza
itali
forwardrevers
primer
design
within
conserv
gene
sequenc
use
primer
express
appli
biosystem
monza
itali
tabl
realtim
pcr
perform
use
taqman
chemistri
fam
tamra
end
label
probe
realtim
reaction
compos
fast
master
mix
appli
biosystem
monza
itali
nm
forwardrevers
primer
mixtur
nm
taqman
probe
steril
water
cdna
experi
perform
use
abi
ht
fast
realtim
pcr
system
follow
condit
min
follow
cycl
second
second
minut
messeng
rna
transcript
level
standard
housekeep
gene
nontreat
retrotranscrib
rna
use
mrna
express
control
sampl
analyz
duplic
quantit
pcr
qpcr
cell
plate
well
mockor
f
infect
moi
treat
cexndi
nm
hpi
cell
collect
total
dna
extract
use
nucleospin
tissu
machereynagel
duren
germani
accord
manufactur
instruct
isol
intracellular
dna
analyz
realtim
pcr
use
taqman
chemistri
fam
tamra
end
label
probe
tabl
final
volum
qpcr
reaction
compos
fast
master
mix
appli
biosystem
monza
itali
nm
forwardrevers
primer
mixtur
gene
tabl
nm
taqman
probe
steril
water
isol
dna
experi
perform
use
abi
ht
fast
realtim
pcr
system
follow
condit
min
follow
cycl
second
second
sampl
analyz
duplic
